What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?
One hundred forty-seven consecutive patients with leukemia, myelodysplastic syndrome, or aplastic anemia were treated by marrow grafts from genotypically HLA-identical siblings (n = 122) or HLA- haploidentical family members (n = 25). Haploidentical recipients differed from their donors for no more than one HLA locus on the nonshared haplotype. All were given postgrafting immunosuppression with a combination of methotrexate and cyclosporine. In a randomized study we explored whether prednisone administered from day 0 through 35 along with methotrexate/cyclosporine could improve prevention of acute graft- versus-host disease (GVHD). The GVHD incidence in patients not given prednisone was comparable with that previously reported with methotrexate/cyclosporine. Unexpectedly, significant increases in acute and also chronic GVHD were seen in HLA-identical recipients administered prednisone, but not in the small number of patients administered HLA-nonidentical grafts. However, the resultant
Related Questions
- Does oxypentifylline reduce the intensity of acute graft-versus-host disease following allogeneic bone marrow transplantation?
- Antithrombotic prophylaxis in patients with von Willebrand disease undergoing major surgery: when is it necessary?
- What percentage of Wilsons Disease patients need liver transplants?
